Nuvalent, Inc. (NUVL)

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The company leverages deep expertise in chemistry and structure-based drug design to develop innovative small molecules that aim to overcome the limitations of existing therapies for clinically proven kinase targets, including kinase resistance, kinase selectivity, and limited brain penetrance.

The company faces substantial competition from pharmaceutical and biotechnology companies, academic institutions, and research institutions. For zidesamtinib, competitors include four FDA-approved ROS1 TKIs: Xalkori (crizotinib), Rozlytrek (entrectinib), Augtyro (repotrectinib), and Ibtrozi (taletrectinib), as well as lorlatinib recommended by NCCN guidelines. For neladalkib, competitors include six FDA-approved ALK TKIs: Xalkori, Zykadia (ceritinib), Alecensa (alectinib), Alunbrig (brigatinib), Lorbrena (lorlatinib), and Ensacove (ensartinib). For NVL-330, competitors include two FDA-approved HER2 TKIs, Hernexeos (zongertinib) and Hyrnuo (sevabertinib), and the antibody-drug conjugate Enhertu (T-DXd). Many competitors have significantly greater financial resources, established market presence, and expertise in research and development, manufacturing, clinical testing, and regulatory approvals.

The company generates revenue through the sale of commercial products, though it has not yet generated any revenue to date. It retains full development and worldwide commercialization rights to its pipeline of precisely targeted therapies. The company is building a fully integrated, commercial-stage biotechnology company capable of discovering, developing, and delivering new medicines for patients with cancer.

The company's lead product candidate, zidesamtinib (NVL-520), is a novel ROS1-selective inhibitor being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). It has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ROS1-positive NSCLC who have previously been treated with two or more prior ROS1 TKIs, and orphan drug designation for ROS1-positive NSCLC. The ARROS-1 clinical trial is a first-in-human global Phase 1/2 study. From January 2022 to August 2023, the Phase 1 portion enrolled 104 patients (99 NSCLC, 5 other solid tumors). The Phase 2 portion initiated in September 2023 with a recommended Phase 2 dose (RP2D) of 100 mg once daily (QD). Between September 2023 and June 16, 2025, 435 patients were enrolled in the Phase 2 portion. In November 2025, the FDA accepted for filing the NDA for zidesamtinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received at least 1 prior ROS1 TKI, with a PDUFA target action date of September 18, 2026 ¹.

The company's second lead product candidate, neladalkib (NVL-655), is a brain-penetrant ALK-selective inhibitor being developed for patients with ALK-positive NSCLC. It has received FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with two or more ALK TKIs, and orphan drug designation for ALK-positive NSCLC. The ALKOVE-1 clinical trial is a first-in-human global Phase 1/2 study. From June 2022 to February 2024, the Phase 1 portion enrolled 133 patients (131 NSCLC, 2 other solid tumors). The Phase 2 portion initiated in February 2024 with a RP2D of 150 mg QD. In July 2025, the ALKAZAR Phase 3 clinical trial was initiated with registrational intent for TKI-naive patients, designed to enroll approximately 450 patients ². In November 2025, positive topline data was announced for neladalkib in TKI pre-treated patients; as of the data cut-off date of August 29, 2025, 781 patients with ALK-positive solid tumors had received neladalkib at any starting dose, and 656 patients with advanced ALK-positive NSCLC were treated at the RP2D ³. The company plans to submit an NDA for neladalkib in TKI pre-treated patients in the first half of 2026.

The company's third product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor designed to address tumors driven by HER2 mutations and alterations, including HER2 exon 20 insertion mutations (HER2ex20), treating brain metastases, and avoiding treatment-limiting adverse events due to off-target inhibition of wild-type EGFR. The HEROEX-1 clinical trial, a global Phase 1a/1b study, is currently enrolling patients with advanced HER2-altered NSCLC. The first patient was dosed in July 2024. The company also has discovery programs and plans to disclose a new development candidate by year-end 2026.

The company has incurred significant net losses in each period since inception and has not generated any revenue. Net losses were $425.4 million ⁴, $260.8 million ⁵, and $126.2 million ⁶ for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the company had an accumulated deficit of $972.4 million ⁷.

A key growth vector is the potential commercial launch of zidesamtinib in the U.S. for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who received at least 1 prior ROS1 TKI, pending FDA review with a PDUFA target action date of September 18, 2026 ⁸. The company also plans to submit data to the FDA for potential label expansion of zidesamtinib in TKI-naive patients with advanced ROS1-positive NSCLC in the second half of 2026. Another major growth vector is the planned NDA submission for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC in the first half of 2026, and the ongoing ALKAZAR Phase 3 randomized, controlled trial of neladalkib for TKI-naive patients with ALK-positive NSCLC, designed to enroll approximately 450 patients ⁹.

The company is progressing the HEROEX-1 Phase 1a/1b trial of NVL-330 for patients with advanced HER2-altered NSCLC and plans to disclose a new development candidate by year-end 2026. The company also continues to evaluate new program areas with a focus on addressing the limitations of existing therapies for other clinically proven kinase targets in oncology.

The company expects to continue to incur significant expenses and net losses for the foreseeable future. Expenses are anticipated to increase over time as the company prepares for the potential commercialization of zidesamtinib, including due to the impact of increased headcount, and to support clinical and commercialization activities and expanded infrastructure.

The company relies on third parties for the manufacture of its product candidates for preclinical and clinical testing, as well as for commercial manufacturing if any product candidates obtain marketing approval. Currently, active pharmaceutical ingredients for zidesamtinib, neladalkib, and NVL-330 are manufactured in accordance with current good manufacturing practices (cGMPs). The company currently relies on vendors as single-source contract manufacturing organizations (CMOs) and is continuing to develop its supply chain, including exploring adding additional backup suppliers. As of December 31, 2025, the company had 228 full-time employees ¹⁰, of which 144 are engaged in research and development ¹¹. The company expects to continue to add additional employees in 2026 with a focus on increasing expertise in commercialization and clinical and preclinical research and development.

The company expects to continue to incur significant research and development expenses. Based on the current operating plan, the company believes that existing cash, cash equivalents, and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into 2029. The company does not intend to pay dividends on its common stock.

The company faces significant risks and uncertainties that could materially affect its business, including the failure to adequately demonstrate safety and efficacy of product candidates in preclinical studies or clinical trials, delays or difficulties in patient enrollment, and the potential for adverse events. The company also faces substantial competition from companies with significantly greater financial resources and established market presence. The company has a limited operating history, has no products approved for commercial sale, and has not generated any revenue.

The company's business is subject to extensive government regulation, and the regulatory approval processes of the FDA, EMA, and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable. Changes in regulatory requirements and policies, such as those related to diversity action plans or the Inflation Reduction Act of 2022, could impact the company's development plans. The company also faces risks related to its reliance on third-party manufacturers and the potential for manufacturing difficulties.

Management's message emphasizes the company's focus on executing its OnTarget 2026 operating plan, which delineates a three-year plan towards bringing new, potential best-in-class medicines to patients with cancer. Key themes include obtaining regulatory approval for zidesamtinib, advancing the clinical development of neladalkib, progressing the ALKAZAR Phase 3 trial, and continuing to expand the pipeline. Management highlights the completion of milestones in 2024 and 2025, including reporting pivotal data for zidesamtinib and neladalkib, completing a rolling NDA submission for zidesamtinib, and initiating the ALKAZAR Phase 3 trial. For 2026, management outlines anticipated milestones leading to the first potential U.S. commercial launch, including the commercial launch of zidesamtinib pending FDA review, submission of data for potential label expansion, submission of an NDA for neladalkib, and disclosing a new development candidate by year-end 2026.

For the year ended December 31, 2025, the company reported a net loss of $425.4 million ¹⁶, compared to a net loss of $260.8 million ¹⁷ for the year ended December 31, 2024, and a net loss of $126.2 million ¹⁸ for the year ended December 31, 2023. The company has not generated any revenue to date. As of December 31, 2025, the company had an accumulated deficit of $972.4 million ¹⁹. Research and development expenses were a significant component of operating expenses, with $144 of the company's 228 full-time employees engaged in research and development as of December 31, 2025 ²⁰. The company's cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditure requirements into 2029.

The company's future prospects are substantially dependent on the success of zidesamtinib, neladalkib, and NVL-330, and failure to advance these product candidates through development, obtain regulatory approval, and commercialize them would materially harm the business. The company has incurred significant net losses in each period since inception, with net losses of $425.4 million ¹², $260.8 million ¹³, and $126.2 million ¹⁴ for the years ended December 31, 2025, 2024, and 2023, respectively, and an accumulated deficit of $972.4 million ¹⁵ as of December 31, 2025, and expects to continue incurring significant net losses. The company faces intense competition from established pharmaceutical and biotechnology companies with significantly greater financial resources, and its product candidates may fail to achieve adequate market acceptance. The company relies on third-party manufacturers as single-source providers, and any disruption in the supply chain could delay or prevent the provision of adequate supply for clinical trials or commercial products.